Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kimberly Clark Corp (KMB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Kimberly Clark CorpTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Kimberly Clark Corp vs Zimmer Biomet Holdings Inc — how do they compare? Kimberly Clark Corp trades at $109.29 (market cap $36.11B), while Zimmer Biomet Holdings Inc trades at $95.69 (market cap $18.55B). The key difference: Kimberly Clark Corp is the larger of the two by market cap, and Kimberly Clark Corp pays the higher dividend (4.72%). Which is the better fit depends on your goals.

KMBZBH
Market Cap
$36.11B$18.55B
Sector
Consumer StaplesHealth
52-Week High
$134.81$107.71
52-Week Low
$93.05$79.58
Enterprise Value
$41.67B$25.61B
Dividend Yield
4.72%0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kimberly Clark Corp

Kimberly-Clark (KMB) trades at $108.02, down 1.51% today, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings missed expectations, prompting a lowered 2026 outlook due to China diaper market weakness and North American volatility. The company maintains strong profitability with a net income margin of 11.79% and a high ROE of 129.43%, but faces revenue pressure with 2025 sales at $16.45B, down from prior years. Dividend payments remain steady at $1.28 per share, supporting income investors.

KMB presents a cautious outlook with near-term headwinds overshadowing long-term strengths. Investment opportunities include a discounted valuation relative to historical levels and a reliable dividend yield. Key risks involve execution challenges in China, competitive pressures, and macroeconomic sensitivity. Analyst consensus is mixed, with a $113.20 price target suggesting modest upside, but investors should weigh operational uncertainties against the company's brand resilience and cost-saving initiatives.

Zimmer Biomet Holdings Inc

ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.

The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Kimberly Clark Corp

With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.

Read more on KMB

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH